Ionis Pharmaceuticals is a biotechnology company that develops RNA-targeted medicines for serious diseases. Its marketed portfolio includes TRYNGOLZA (olezarsen) for familial chylomicronemia syndrome, DAWNZERA (donidalorsen) for hereditary angioedema, WAINUA (eplontersen) for hereditary transthyretin-mediated amyloidosis, SPINRAZA (nusinersen) for spinal muscular atrophy, QALSODY (tofersen) for amyotrophic lateral sclerosis, TEGSEDI (inotersen) for amyloidosis, and WAYLIVRA (volanesorsen) for familial chylomicronemia syndrome. The company operates in the United States, Europe, China, Canada, Brazil, and Japan. Ionis partners with Biogen for the global commercialization of SPINRAZA and QALSODY, with AstraZeneca for WAINUA, with Sobi for TEGSEDI and WAYLIVRA in Europe, with PTC Therapeutics for Latin America, and with Otsuka for DAWNZERA in Europe and Asia. Its pipeline includes olezarsen for severe hypertriglyceridemia, zilganersen for Alexander disease, obudanersen for Angelman syndrome, bepirovirsen for chronic hepatitis B, and sapablursen for polycythemia vera.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage ionis.com
Sector Healthcare IR page ir.ionis.com
Tags
antisense oligonucleotides, rna-targeted medicines, neurology, cardiometabolic diseases, rare diseases, spinal muscular atrophy, amyotrophic lateral sclerosis, hereditary angioedema, familial chylomicronemia syndrome, amyloidosis, chronic hepatitis b, angelman syndrome, TRYNGOLZA, olezarsen, DAWNZERA, donidalorsen, WAINUA, eplontersen, SPINRAZA, nusinersen, QALSODY, tofersen, TEGSEDI, inotersen, WAYLIVRA, volanesorsen, zilganersen, obudanersen, bepirovirsen, sapablursen, sefaxersen, Biogen, AstraZeneca, Sobi, PTC Therapeutics, Otsuka, Roche
Press page —

Metrics

Valuation  
Market cap $ 4.932B
Market cap (USD) $ 4.932B
P/E -9.09
PEG —
P/BV 12.53
P/S 5.14
P/OCF -9.06
P/FCF -8.00
Dividend yield —
Turnover / mcap —
Returns  
ROE -70.8%
ROI -17.0%
ROIC -12.7%
Profit margin -40.4%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 359.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 134
Quality score -61.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 943.711M 705.138M 787.647M 587.367M 810.456M 729.264M 1.123B 599.674M 507.666M 346.62M 283.703M 214.161M 147.285M 102.049M 99.086M 108.473M 121.6M 107.19M 69.621M 24.532M 40.133M 42.624M 49.99M 80.179M 53.273M 37.255M
Net profit -381.387M -453.897M -366.286M -269.722M -28.597M -451.286M 294.146M 273.741M -5.97M -86.556M -88.278M -38.984M -60.644M -65.478M -84.801M -61.251M 155.066M -11.963M -136.305M -45.903M -72.401M -142.503M -94.996M -72.242M -73.832M -53.485M
Free cash flow -320.027M -546.227M -331.318M -290.091M 18.844M 772K 314.815M 589.28M 139.385M -119.212M 13.433M -1.233M 61.941M 397K -122.132M -76.83M -121.855M 198.366M 33.801M -54.267M -62.163M -105.277M -103.028M -131.215M -15.445M -24.835M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 79.11 34.96 50.59 37.77 30.43 56.54 60.41 54.06 50.3 47.83 61.93 — — — — 40 — — — — — — — — — —
Price performance 12m 1.26 -0.31 0.34 0.24 -0.46 -0.06 0.12 0.07 0.05 -0.23 — — — — — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) 1.19M 1.62M 13.7M 2.03M 300M — 151,000 157,000 165,000 432M
Borrowings, non-current (USD) — — — 786M 539M — 1.18B 1.24B 1.2B 1.33B
Lease liabilities (USD) — — — 2M 2M 2.6M 186M 179M 171M 272M
Cash and deposits (USD) 84.7M 130M 279M 683M 398M 869M 276M 399M 242M 372M
Intangible assets (USD) 20.4M 22M 24M 25.7M 27.9M 29M — — — —
Right-of-use assets (USD) — — — 12.6M 13.1M 18M 182M 172M 162M 239M
Net debt (borrowings + leases - cash) (USD) -83.5M -128M -265M -679M 444M — 1.09B 1.02B 1.13B 1.66B
Cash flow detail
Operating cash flow (USD) -112M 174M 603M 346M 35.9M 30.8M -274M -308M -501M -269M
Purchases of property, plant and equipment (USD) -7.11M -34.8M -13.6M -30.9M -35.1M -12M -15.7M -23.8M -45.3M -51.4M
Purchases of intangible assets (USD) — — — -5.38M -5.93M -5.95M -4.38M -4.21M -5.06M -5.64M
Change in inventories (cash effect) (USD) -590,000 -2.49M 1.4M -5.41M -1.26M -2.84M 2.77M -6.39M -5.07M -13.7M
Change in payables (cash effect) (USD) -10.7M 1.78M -655,000 -16.3M -2.76M -6M 1.09M 8.12M 16M -15.4M
Share buybacks (cash effect) (USD) — 0.00 0.00 -34.4M -90.5M 0.00 0.00 — — —
Interest paid (cash effect) (USD) -7.31M -8.04M -9.59M -9.87M -6.25M -4.78M -2.9M -6.51M -10.9M -10.8M
Income taxes paid (cash effect) (USD) — 0.00 0.00 -9.04M -25.9M -38,000 -5.01M -48.3M 5.62M 639,000
Share-based compensation (USD) 72.1M 86M 131M 147M 230M 121M 100M 106M 130M 134M
Free cash flow (OCF - PPE - intangibles) (USD) -119M 139M 589M 315M 772,000 12.9M -294M -336M -551M -326M
Income detail
Research and development expense (USD) 340M 373M 412M 462M 531M 638M — 900M 902M 916M
↳ 5y CAGR +16.7% +18.6% +18.8% +14.1% +10.7% +13.4% +16.9% +14.3% +11.5%
Total comprehensive income (USD) -103M -18.7M 215M 310M -483M -40.2M -295M -341M -452M -376M
Comprehensive income to owners (USD) -103M -7.28M 274M 301M -447M -40.2M -295M -341M -452M -376M
Reported Feb 28, 2018 Mar 2, 2020 Mar 2, 2020 Feb 25, 2022 Feb 25, 2022 Feb 25, 2022 Feb 22, 2023 Feb 26, 2026 Feb 26, 2026 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

– ZANVASTROTM (zilganersen) first approved medicine for Alexander disease; first independent launch underway from leading neurology pipeline –

– TRYNGOLZA® (olezarsen) 2026 product sales guidance lowered as sHTG launch ramps more gradually than expected reflecting early dynamics of establishing a new treatment paradigm –

– DAWNZERA® (donidalorsen) launch momentum continues; reaffirming 2026 product revenue guidance –

– Reaffirming 2026 total revenue, operating loss and cash guidance –

CARLSBAD, Calif., November 9, 2026 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the third quarter ended September 30, 2026.

“In 2026, we continue to advance innovative medicines for people with serious diseases, underscored by three approvals for groundbreaking first-in-class medicines, two of which are Ionis-owned,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “TRYNGOLZA, our first launch in a large indication, represents a new treatment paradigm for the underserved sHTG population.

November 2, 2026

More than three million people in the United States are living with very high triglycerides 500 mg/dL or higher, also known as severe hypertriglyceridemia (sHTG), yet many are left to navigate a complex care journey largely on their own.  

Clinical guidelines provide evidence-based recommendations for identifying and managing very high triglycerides, including reducing the risk of one of its most serious and potentially life-threatening complications – acute pancreatitis. Despite this, many people spend years searching for answers and piecing together information about their diagnosis. Some may not fully understand the importance of protecting against the risk of acute pancreatitis until they experience this medical emergency themselves.  

With support from Ionis, the Hidden in Plain Sight white paper was developed in partnership with the National Triglyceride Alliance, leading clinicians, patient advocates, people living with very high triglycerides and their care partners to examine the gap between recognition and care and the collective action required to close it.  

Here are four key takeaways from the paper:  

  1. Close the information and care gaps: Although clinical guidelines offer clear, evidence-based recommendations, those recommendations are not consistently applied in routine patient care. Gaps in education, referrals, integrated care or long-term follow-up can leave people without the information or support they need.  

    At diagnosis, patients should receive a clear explanation of the diagnosis and its risks as well as a personalized plan that addresses appropriate lifestyle modifications and medical therapy. Timely referrals to specialists and an established follow-up plan are also essential to support long-term care.  
     

"We need to raise awareness amongst our medical colleagues. We must all carry a sense of urgency in guiding people with severely elevated triglycerides toward help before they get to the point of pancreatitis or before they get recurrent pancreatitis."

Ann Liebeskind, MD, FNLA, FAAP, FACC Clinical Contributor

  1. Educate about the risks of acute pancreatitis before the first attack occurs: Reducing the risk of acute pancreatitis is one of the most important goals of identifying and managing very high triglycerides early. A single acute pancreatitis attack can have devastating consequences, including organ failure, diabetes caused by pancreatic injury or even death. Due to a lack of education, many patients do not even learn about the risk of acute pancreatitis associated with very high triglycerides until they experience an attack.  

    Education must happen earlier so patients can develop a management plan with their care teams before their first attack.  

  2. Reduce the stigma and provide individualized support: Patients have described being told to lose weight, improve their diet or exercise more, even when they were already taking those steps. Those experiences left many feeling that their condition was being viewed as a lifestyle choice or personal responsibility, rather than a complex medical condition.  

    Conversations about very high triglycerides should reflect its biological complexity and be approached with curiosity, empathy and individual assessment. Reducing blame can help patients feel heard, reduce the stigma and strengthen trust between patients and their care teams. 

"I'd like patients to know that there are options for them and that this is not always just a lifestyle thing. They shouldn't blame themselves."

Nishant Shah, MD Clinical Contributor

  1. Multidisciplinary care should become the standard, not the exception: People living with very high triglycerides may benefit from a coordinated care team across healthcare professionals, including primary care, lipid specialists and registered dietitians, among other team members. However, this level of support is not always offered.

    Expanding access to multidisciplinary care, establishing shared care plans and coordinating follow-up can help ensure every member of the care team works toward the same goals. No patient should ever feel alone. 

Learn More

Visit the National Triglyceride Alliance website to read the full paper .  

Article tags: Cardiometabolic Disease

Ionis Logo Black & White

Footer menu

©1989-2026 Ionis Pharmaceuticals, Inc. All rights reserved.

You are now leaving https://www.ionis.com to visit 

Continue to site  

Cancel

Back to top

Ionis Ranked #1 Top Employer by Science Bull 1 Bear 0 Other

October 23, 2026

We are excited to be recognized as Science’s #1 Top Employer for 2026. In only our second year of eligibility, this honor highlights our industry-leading innovation , talented employees and strong values-based culture . 
 

Hear from some of our talented employees and one of our executives about what makes Ionis a special place to do their best work and pursue medical breakthroughs that have the potential to improve people’s lives.

Paymaan, Executive Director, Neurology, shares how bold science and a commitment to patients inspire Ionis to embrace big challenges.

A group in Ionis shirts gathers on a beach beside a Surf Away+ sand sculpture. Text highlights recognition for a strong values-based culture.

Maureen, Senior Manager, GMP QA, shares how a focus on patients, collaboration and connections with families make working at Ionis meaningful.

Three Ionis scientists in lab coats examine images on a computer screen in a laboratory. Text reads: “Industry-leading innovation.”

Vince, Director, HCP Marketing, shares how colleagues’ strengths and a shared commitment to patients inspire new thinking at Ionis.

Three Ionis employees in protective clothing work with stainless steel processing equipment in a facility. Text reads: “Talented employees.”

Holly Kordasiewicz, Chief Development Officer, shares how taking on new challenges to make a difference for patients shapes Ionis’ culture.

Image 1 of 7

Does this sound like a place where you could grow your career? Learn more about our award-winning workplace at ionis.com/careers . 

Science and Science Careers’ 2026 Top Employers Survey findings reflect approximately 5,100 responses from readers of Science and other invitees. Respondents to the web-based survey were asked to rate companies based on 24 characteristics.

Prompts

Ionis Pharmaceuticals, Inc. (ticker IONS), listed in United States.

Company History

Date Change Detail
Dec 18, 2015 Renamed ISIS PHARMACEUTICALS INC → IONIS PHARMACEUTICALS INC

ETFs Holding Ionis Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
MEDX 4.53% 10,904 $ 864.578K Jun 30, 2026
TMFS 3.40% 32,785 $ 1.979M Aug 31, 2026
TMFM 2.52% 49,761 $ 3.004M Aug 31, 2026
FFOX 2.06% 62,476 $ 4.954M Jun 30, 2026
HELX 1.91% 6,739 $ 534.335K Jun 30, 2026
ARKG 1.40% 943,418 $ 25.435M Nov 18, 2026
DWSH short -0.94% -2,155 $ -58.099K Nov 17, 2026
SSMG 0.87% 540 $ 27.956K Jul 31, 2026
FFND 0.73% 11,925 $ 719.793K Aug 31, 2026
TAX 0.68% 2,851 $ 172.086K Aug 31, 2026
COPY 0.63% 43,585 $ 2.631M Aug 31, 2026
FLDZ 0.42% 216 $ 17.127K Jun 30, 2026
TMSL 0.35% 118,398 $ 9.388M Jun 30, 2026
CGMM 0.28% 366,601 $ 10.268M Nov 16, 2026
HRTS 0.26% 2,427 $ 146.494K Aug 31, 2026
MSSM 0.25% 29,552 $ 1.784M Aug 31, 2026
TMED 0.18% 509 $ 40.359K Jun 30, 2026
CGGR 0.16% 1,473,768 $ 41.28M Nov 16, 2026
BALQ 0.16% 2,457 $ 68.821K Nov 16, 2026
FFLG 0.14% 16,403 $ 849.183K Jul 31, 2026
NBCR 0.11% 15,525 $ 937.089K Aug 31, 2026
REMC 0.09% 38 $ 3,013.02 Jun 30, 2026
FTHI 0.08% 73,191 $ 2.05M Nov 16, 2026
BALI 0.07% 35,755 $ 1.001M Nov 16, 2026
FTQI 0.06% 20,471 $ 573.393K Nov 16, 2026
WSGE 0.06% 1,265 $ 34.104K Nov 18, 2026
AVIE 0.04% 251 $ 7,030.51 Nov 16, 2026
IALT 0.02% 49,537 $ 1.388M Nov 16, 2026
MSLC 0.02% 12,074 $ 728.787K Aug 31, 2026
JSTC 0.01% 793 $ 22.212K Nov 17, 2026
DYNF 0.00% 264 $ 7,394.64 Nov 16, 2026
NTRL short 0.00% -4,538 $ 0.00 Nov 16, 2026